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Background
T cell immunotherapy is one promising approach to
improve outcomes for patients with AML; however,
infused T cells do not redirect resident T cells to
tumors. To overcome this, we have genetically modified
T cells to produce a secretable, bispecific T cell engager
(ENG-T cells). Consistent synthesis of engagers by
T cells should be superior to the direct infusion of the
recombinant bispecific antibody, because bispecific pro-
teins typically have short half-lives and do not accumulate
at tumor sites. The goal of this project was to generate
and characterize T cells expressing CD123-specific enga-
gers and evaluate the feasibility of using transgenic
expression of CD20 in combination with rituximab as a
suicide gene.
Methods
CD123-ENG T cells were generated by transducing T cells
with a retroviral vector encoding a CD123-specific T cell
engager consisting of a scFv recognizing CD123 linked to
a scFv recognizing CD3. The vector also contained mOr-
ange or CD20 as a second transgene. Effector function
of CD123-ENG T cells was evaluated in vitro and in a
xenograft model. Toxicity of CD123-ENG T cells and
the functionality of the suicide gene were evaluated in
vitro and in vivo.
Results
Mean transduction efficiency was 76% (49-95%), and
CD123-ENG and CD20.CD123-ENG T cells recognized
CD123+ cells (MV-4-11, MOLM-1, KG1a, K562-CD123)
as judged by cytokine production and cytolytic activity.
CD123-negative cells (K562) were not recognized by
CD123-ENG T cells. Likewise, control ENG-T cells were
not activated by CD123+ cells. Antigen-dependent recog-
nition was confirmed with cytotoxicity assays. Since
CD123 is expressed on normal hematopoietic progenitor
cells (HPCs), we evaluated the ability of CD123-ENG
T cells to recognize normal HPCs in colony formation
assays. Only at high CD123-ENG to HPC ratios did we
observe a decline in colony numbers. In contrast, toxicity
to primary leukemia samples was apparent even at low
CD123-ENG T cell:leukemia cell ratios, indicating that
CD123+ AML cells can be targeted while preserving nor-
mal HPCs. In vivo, CD123-ENG T cells and CD20.
CD123-ENG T cells had potent anti-tumor activity in the
KG1a/NSG xenograft model resulting in a significant sur-
vival advantage of treated animals in comparison to mice
that received Control-ENG T cells (p=0.002). Lastly,
CD20.CD123-ENG T cells were efficiently eliminated by
rituximab in the presence of complement in contrast to
CD123-ENG T cells.
Conclusions
We have generated CD123-ENG T cells that can direct
bystander T cells to CD123+ AML in an antigen-specific
manner. These CD123-ENG T cells have powerful anti-
AML activity in vivo and when further engineered to also
express CD20, are eliminated by rituximab. These cells
may present a promising addition to currently available
AML therapies.
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